History

Throughout its 300-year history,
ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

A history of 300 years

 

The history of 300 years during which
ONO has made progress from its
founding in 1717 to the present.

History

Founding

Founding of the Apothecary “Fushimiya Ichibei” (Fushi-Ichi)

1717
The first Ichibei Ono set up the apothecary “Fushimiya Ichibei” in Doshomachi, Osaka.
1934
Reorganized to an unlimited partnership, and changed the name to “Ono Ichibei Shoten”.
1947

Transition from Ono Ichibei Shoten to ONO PHARMACEUTICAL

1947
ONO PHARMACEUTICAL CO., LTD. was established.
1962
Listed on the Osaka Securities Exchange.
1963
Listed on the Tokyo Stock Exchange.
1968

Working towards Shifting in Marketing and R&D from OTC Drugs to Prescription Drugs

1968
Completion of the Central Research Institute (Current the Minase Research Institute)
Made a world-first success of total synthesis of prostaglandin (PG) as a public corporation.
1975
Completion of the Fujiyama Plant
1978
Completion of the new head office building (Current the head branch)
1982
The London office was opened in the United Kingdom.
1985
Completion of the Fukui Research Institute for safety assessment
1990
The Seattle office was opened in the United States.
1994
The Seoul office was opened in South Korea (Later Seoul Branch).
1995
Completion of the new building for Tokyo Branch (Current the Tokyo Office)
1998
ONO PHARMA UK LTD. and ONO PHARMA USA, INC. were established.
(The London office and the Seattle office developed into ONO PHARMA UK LTD. and ONO PHARMA USA, INC., respectively.)
1999
Completion of the Fujiyama Plant
2003

Delivering Innovative New Drugs to Patients around the World

2003
The Tsukuba Research Institute was opened.
Completion of the new Head Office building
2013
ONO PHARMA KOREA CO., LTD. was established in South Korea
(The Seoul office developed into ONO PHARMA KOREA., LTD.)
2014
ONO PHARMA TAIWAN CO., LTD. was established in Taiwan.
Launched the world's first anti-PD1 antibody, OPDIVO Intravenous Infusion, in Japan.
2016
Completion of the new Research Building (The Third Building) in the Minase Research Institute
2018
Completion of the Tokyo Building
2019
Completion of the Yamaguchi Plant
2020
Ono Venture Investment, Inc. was established in the United States.
Ono Venture Investment Fund I, L.P. was established in the United States.
2021
Ono Pharma Healthcare Co., Ltd. was established.
2022
Closure of the Fukui Research Institute. (It's functions were consolidated into the Minase Research Institute.)
Ono Digital Health Investment, GK was established.
Ono Pharma UD Co., Ltd. was established.
michiteku Co., Ltd. was established.
2023
OPhrs Co., Ltd. was established.
2024
Ono acquired Deciphera Pharmaceuticals, Inc., a US biopharmaceutical compnay.